# Ep3: George Yancopoulos

- **Show:** The Long Run with Luke Timmerman
- **Published:** 10 Oct 2017
- **Source:** https://soundcloud.com/longrunpodcast/ep3-george-yancopoulos
- **Transcript:** https://podcasts.opennash.com/shows/the-long-run/ep3-george-yancopoulos-bd1f4d/
- **Provider:** OpenNash Podcasts (machine-generated)

## In brief

George Yancopoulos, Regeneron's president and chief scientist, argues that lasting drug innovation comes from a science-led culture that builds many deep capabilities, such as human antibodies, mouse genetics and human genetics, rather than relying on one trick. He says this long-term approach explains why Regeneron has produced six approved drugs from its own labs.

The central tension is between short-term pressures and long-term innovation. Yancopoulos says quarterly numbers and annual price increases distract from the real problem, which he calls a lack of R&D innovation. He argues that fair pricing is affordable when drugs are truly innovative, and that policy should reward long-term research behavior rather than only punishing high prices.</ol>

## Key insights

1. **Scientist-led culture drives Regeneron's long-run success** Yancopoulos says scientists are the most revered people at Regeneron, which helps it recruit top researchers, and he points to key early scientists who have stayed for decades. He contrasts this with Merck after Roy Vagelos and Genentech, which he says lost research strength as commercial leaders took over.
2. **Breadth of technologies beats any single trick** Regeneron combines fully human antibody mice, trap technology, mouse genetics and large-scale human sequencing. Yancopoulos says antibody-only rivals like Medarex and Abgenix faded, while Regeneron's layered capabilities and independent strategy kept it going.
3. **Human genetics evidence reduces late-stage failures** Regeneron builds up evidence step by step, from human genetic variation to mouse models to antibodies, before pushing programs forward. Yancopoulos says this is why it rarely sees late-stage failures, and why it pursues examples like PCSK9, where gene discoveries pointed to the target.
4. **Eylea won through better data, not price cutting** Yancopoulos says Eylea was priced only a few dollars below Lucentis per injection. Its edge came from trial data showing half as many injections with comparable or better control of eye swelling, and a National Eye Institute study showing one to two lines of improvement on the eye chart.
5. **Price hikes are a symptom of weak innovation** Yancopoulos says companies like Pfizer lean on price increases because they lack new drugs to drive growth, comparing it to a cough from lung cancer. He argues policy should create incentives for R&D rather than simply attacking prices.

## Questions this episode answers

### Why has Regeneron succeeded when so many antibody companies disappeared?

Yancopoulos says Regeneron stayed independent instead of aiming to be bought out, and its antibody mice were backed by many other technologies. Rivals such as Medarex and Abgenix were mostly antibody companies.

### Did Regeneron really undercut Genentech's Lucentis on price with Eylea?

Only slightly, according to Yancopoulos, who says Eylea was just a few dollars cheaper per injection. Its main advantage was trial data showing patients needed half as many eye injections.

### Why does Yancopoulos say drug price increases are not the real problem?

He calls them a symptom of an industry that is not producing enough new drugs. He says big companies raise prices because they cannot grow through innovation.

### What is the Regeneron Genetics Center and why would a company run one?

It is Regeneron's large DNA sequencing effort, which connects human genetic differences to disease. Yancopoulos says this helps validate drug targets and discover new ones, and he calls it the largest human sequencing operation in the world.

### How does Yancopoulos say a company should decide which programs to push forward?

He says Regeneron keeps stacking up evidence from human genetics, mouse models and antibody tests, and pauses programs when the data weakens. It rarely pushes ahead without strong data, which he says is why late-stage failures are rare.

## Facts

- **Luke Timmerman** [0:00:45]: "The company has developed six FDA-approved drugs so far, and it's the third best-performing stock in the S &P 500 over the past decade."
- **George Yancopoulos** [0:09:04]: "Last year, 2016, 22 medicines approved by the FDA. Only eight of them. Only eight of them first in class."
- **George Yancopoulos** [0:10:25]: "it was my mentor Fred Ault and I in 1985 that actually made the first proposal to make these mice that could make human antibodies."
- **George Yancopoulos** [0:10:25]: "And we actually collaborated. We had an important collaboration with Medarex."
- **George Yancopoulos** [0:11:12]: "he helped create a business plan and structure where we would stay independent. Whereas a lot of these other companies, their goal was to sort of get bought out."
- **George Yancopoulos** [0:17:29]: "where we now have two plants, one up at Ronsolier and one in Ireland, in Raheem in Ireland."
- **George Yancopoulos** [0:28:09]: "We just recently announced a major initiative where we're going to be sequencing the UK biobank of 500 ,000 people."
- **George Yancopoulos** [0:29:22]: "Our first drug approval, which is our IL-1 trap or ARKELIST in cold-induced inflammatory syndrome, was perhaps the first example"
- **George Yancopoulos** [0:30:03]: "85 % average improvement in a horrific disease. That's how you want genes to work."
- **George Yancopoulos** [0:30:03]: "where we got the first approved anti-PCSK9 agent for lowering cholesterol"
- **George Yancopoulos** [0:37:01]: "We actually showed head to head that we can inject half as frequently and get as good data."
- **George Yancopoulos** [0:38:09]: "the National Eye Institute and the National Institutes of Health did side-by-side studies, which are rarely done"
- **George Yancopoulos** [0:38:57]: "we priced in a brand new space. There was no other biologics for atopidermatitis."
- **George Yancopoulos** [0:39:29]: "we price our drug at less than half the price of the average psoriasis drugs just because we think it's the appropriate thing to do."
- **George Yancopoulos** [0:42:36]: "It's a little silly from my perspective that we're investing as a nation $30 billion to attack what are arguably some of the most important challenges we have"
- **Luke Timmerman** [0:45:32]: "Allergan comes out with this patent gambit where they transferred over to an Indian tribe with sovereign immunity so that generic companies can't challenge their patents in court."
- **George Yancopoulos** [0:47:28]: "Brown and Goldstein, Nobel Prize winners that have been working together since the 70s."
- **George Yancopoulos** [0:53:10]: "I think that this summer we had 250 interns."
- **George Yancopoulos** [0:53:58]: "So many of us, including Len and I, are actual alumni of that program."
- **George Yancopoulos** [0:34:31]: "Pfizer, in a late stage, phase three trials stage after they spent billions, they failed, which shows how hard this business is."

## Transcript

**[0:00:08] Luke Timmerman:** Welcome to the Long Run. This is a podcast for biotech adventurers. I'm your host, Luke Timmerman. Today's episode features a conversation with George Yancopoulos. He's the president and chief scientist at Regeneron Pharmaceuticals in Tarrytown, New York. Since the late 1980s, he and CEO Len Schleifer have built this company together. These two recall the lean years, when investors wondered if they were backing a science project or helping build a real drug company. But Regeneron has proven itself.

**[0:00:45] Luke Timmerman:** It has broken out as one of biotech's big success stories. The company has developed six FDA-approved drugs so far, and it's the third best-performing stock in the S &P 500 over the past decade. Now Regeneron is attempting to lay the foundation for many more drugs by investing in an ambitious genomics-based drug discovery center. Yancopoulos and Schleifer have strong opinions about the kind of science-based culture they want to create on drug pricing and about how they can keep their edge.

**[0:01:15] Luke Timmerman:** Yancopoulos is a forceful personality. You'll hear his passion for science come through clearly in this conversation. I think you'll enjoy it. Now before we get started, a couple quick plugs. If you like this show, you'll love my subscription newsletter, Timmerman Report. You can go to TimmermanReport.com to subscribe, either as an individual or with a group discount for your company or university. As for this podcast, if you are interested in sponsorship opportunities, this is a great way to get your company's name in front of a high-value audience of biotech executives and investors who are listening.

**[0:01:49] Luke Timmerman:** Send me an email, luke at TimmermanReport.com. The next episode of The Long Run will feature a conversation with Richard Popps, the CEO of Alkermes, about his company's anti-addiction drug and the role it can play in combating the opioid painkiller addiction crisis. This is a serious conversation and an uncomfortable one at times. You won't want to miss it. Now, join me for The Long Run. George Yancopoulos, President and Chief Scientific Officer, is joining me here today at Regeneron Pharmaceuticals for the long run.

**[0:02:26] Luke Timmerman:** Welcome, George.

**[0:02:28] George Yancopoulos:** Welcome to you, to Regeneron and visit our facilities.

**[0:02:31] Luke Timmerman:** Great to be here. So, when I was thinking about coming here, this is my first visit to Regeneron. After years and years of writing about the industry and on occasion some of the main events at your company, You have been here since 1989 with Len Schliefer. Len Schliefer. Okay, all right. Sorry. And this was just a small thing. You're in your late 20s at this time. You trained as a scientist, both you and Len. And what did you envision creating here back then?

**[0:03:11] George Yancopoulos:** Well, Len pretty much called me out of the blue. Before there was any labs or any facilities, it was pretty much just a dream. And at the time, biotech was sort of a dirty word. There were very few cases, if any, of successful scientists moving to biotech. And in fact, all my mentors and heroes were very concerned that I was considering leaving academia to join up with this guy. But I really fell in love with Len.

**[0:03:46] George Yancopoulos:** I really thought that he had, that first of all, he was a very ethical guy. I felt that he really was dreaming the right dream. And I thought that we could really synergize well together. And part of it was also, you know, it was the right time in my life. You know, my dad kept telling me, you know, if you really believe you can do something big in science, and you're depending on these government grants, and you're just going to be talking about curing diseases, if you're really thinking you can cure disease, this is the greatest country in the world.

**[0:04:23] George Yancopoulos:** Do something big. And that was right around the time that I met Len. And so we decided to get together and take it on. I have to admit that I thought that it was going to be a lot easier and a lot faster. I am not sure if I really knew what a long haul it would really be, you know, what I would have thought back then. But for sure, if I knew how it would turn out, I would do this every time.

**[0:04:54] Luke Timmerman:** I think I've heard you say once before that this was an overnight success story that took 25 years.

**[0:04:59] George Yancopoulos:** Exactly. That's exactly right.

**[0:05:01] Luke Timmerman:** It's the nature of the business.

**[0:05:03] George Yancopoulos:** Yeah. Well, I think that, of course, sometimes people get lucky and there's probably other routes to success. But if you really want to build something that's really sustainable, something that has truly the ability to go from discovery to important new medicines that can help patients and doing it over and over again, particularly across all biologic and disease areas, you can't do that overnight. It really takes, as it took in our case, decades of building the background.

**[0:05:39] George Yancopoulos:** And we're still building the background capabilities and technologies. We're always trying to come up with new things and new inventions because that's what you have to be doing. But it is all about developing the foundational capabilities and continuing to innovate and come up with new foundational capabilities that allow you to attack, I think, the hardest challenges facing mankind, which is understanding our biology and taking advantage of that understanding to make an impact in disease.

**[0:06:09] Luke Timmerman:** Now, I want to talk about some of the more current events later, but let's get started here with those early days. I mean, you had trained as a scientist. Now, sometimes you hear people talk about how it's important that biotech companies be led by scientists. But, I mean, scientific training is really good in certain respects, but doesn't prepare you for everything that you have to do, the way it's classically done in academia. So why does it matter?

**[0:06:42] Luke Timmerman:** What is it good for, being trained as a scientist?

**[0:06:45] George Yancopoulos:** Well, I think that that's the notion of scientists. It's being good to have scientists leading biotech companies is sort of an older notion and then a brand new notion. I mean, back in the days of Roy Vagelis at Merck, he was the paradigm. He was the example that everybody pointed to. Look, this is a guy. He's a top-notch scientist who went from academia to becoming head of R &D, and he built Merck into what became the most admired company in the world and the example for all of us in the history of the biopharma industry in terms of science and innovation leading to new important drugs.

**[0:07:27] George Yancopoulos:** I think everybody forgot it. Merck forgot it. As soon as he left, he recommended a scientist take over for him. They put a commercial guy in charge. Some link that to the problem subsequently at Merck. And I think we went through a period of decades where, in fact, for the first 20 years, when Len and I were in charge of Regeneron, people say, hey, this is the problem. This is what you get when you put scientists in charge.

**[0:07:54] George Yancopoulos:** Because we had, from the outside, very little to show for those 20 years. But what people don't realize is that if anything worthwhile in the science world, you have to build. And it's not going to look from the outside as if there's dramatic commercial successes while you're building the science. I think, in fact, we sort of became the new paradigm when Regeneron took off and became one of the most successful examples. and one of the only recent examples of a biotech company completely built from scratch that really has made it into one of the top five biotech companies in the world, all of a sudden people said, wow, maybe that's how we should do it.

**[0:08:33] George Yancopoulos:** Maybe we should put scientists in charge. So we're hearkening back to the ancient models of the 70s and 80s with Roy Vagilis and people are maybe realizing that this is a business where, as I said, people don't realize how hard it is. I believe quantifiably may be the hardest thing that we do as human beings. Look at the odds. 5 ,000 biotech companies in the United States, not to mention hundreds of major medical institutions, millions of researchers.

**[0:09:04] George Yancopoulos:** Last year, 2016, 22 medicines approved by the FDA. Only eight of them. Only eight of them first in class. Most of them for orphan diseases treating just a few thousand people. Very few drugs really impacting lots of people suffering from all the important diseases we know about.

**[0:09:25] Luke Timmerman:** It was a down year. There were a couple good years before that.

**[0:09:28] George Yancopoulos:** Well, but the numbers don't vary by more than twofold. Right. So, you know, you might be talking 20 or 30 or 40 in a good year, but that's still disappointing. And the ones that are really new medicines is still, you know, in the single digit rate, especially those that aren't addressing orphan diseases. Why is that? because it is so hard, because so many people aren't doing it the right way. If you look at the numbers from Regeneron, we actually have a sensible fraction of the world's production, one in 5 ,000 companies.

**[0:09:59] George Yancopoulos:** Why? Because I think we built it right.

**[0:10:01] Luke Timmerman:** So let's come back to those early days. You had some antibody technology, right? Quite a few other companies did too. I mean, I could rattle off a list of, I think, contemporaries from that period, You know, Abgenix, CAT, PDL, Metarex, they're all gone. Why are you still here?

**[0:10:25] George Yancopoulos:** Well, ironically enough, it was my mentor Fred Ault and I in 1985 that actually made the first proposal to make these mice that could make human antibodies. mice. And then other companies, in fact, Fred advised and collaborated with other companies, most notably Medarex and Abgenix, to make the first such mice. And we actually collaborated. We had an important collaboration with Medarex. I think there's a couple examples, I think, why we have survived and thrived and many of those companies have gone by, even though I think that those were great companies.

**[0:11:12] George Yancopoulos:** Part of it was just business strategies. And to give a lot of credit to Len, I mean, he helped create a business plan and structure where we would stay independent. Whereas a lot of these other companies, their goal was to sort of get bought out. The other thing that we have to credit is that I think that the data actually show that even though we weren't the first, like I said, Fred and I were the first to propose making such mice, We weren't the first to succeed to make such mice, but the data show that our technology really is arguably the best.

**[0:11:44] George Yancopoulos:** So the best technology in the right business framework, but just as importantly, for these other companies, the technology was the primary foundation of the company. While it is a foundational technology for us, we are buttressing it, supporting it, amplifying it, synergizing with myriad other capabilities and technology. So for us, we can best take advantage of the best antibody technology because we have the best biology. We have the best target validation technology. We have the best target discovery technology.

**[0:12:18] George Yancopoulos:** And so it's a huge, important component for us. But it's supported by all these other critical foundation technologies. So a lot of other companies were only antibody companies. We were an antibody company. We were also a trap company. We were also, you know, the mouse genetics company. We were also the company that was revolutionizing new ways of doing biology. We're now also, I think, the leading human genetics company. So we're many different companies, many different capabilities come together, and certainly the best antibody, fully human antibody technology, helps turn a lot of those capabilities into important human therapeutics.

**[0:12:58] Luke Timmerman:** So you layer in those technologies over time. As it becomes more clear that you need this piece, you need that piece, Is that a reflection of that scientific mindset? I mean, you alluded to this earlier about roivagelos, and I don't know if you've used the word culture, but I thought you were getting there. When you said we in the industry look to that as the example. And that sounds like what you want this to be. Maybe this becomes a self-fulfilling prophecy.

**[0:13:31] Luke Timmerman:** You've got scientists at the top. You then recruit more scientists. They have more ideas about technologies that you can layer in.

**[0:13:38] George Yancopoulos:** I couldn't have said it better myself yet. It's about the culture. It's about starting with the science, about scientists like us recognizing and recruiting the best other scientists to join us in these efforts. Once you have that culture and once you're devoted to the science and the science is driving everything, and once the scientist is the primary figure in the company, the most revered people in this company are the scientists, that makes it easier to get the best scientists to join you.

**[0:14:08] George Yancopoulos:** If you're a big pharma company and commercial is in charge and so forth, you're not going to get the best people. But when it starts with the scientific culture driving it, everybody's looking at the scientists for the leaderships, then you get the best scientific leaders. And I should point out, I mean, obviously, there was Roy Vagilis and Mark, that was a great example for us. I think Genentech, particularly in the 80s and the 90s. And unfortunately, their success came a little too late for them to hold on to their real research underpinnings and people, because a lot of the people who really built the great Genentech from the research side were gone by the time the 2000s came, and they

**[0:14:49] George Yancopoulos:** had all their commercial successes. So we could see as the commercial success was going on, they hadn't maintained that real scientific ingenuity and drive and foundation that had actually built them. We are very lucky in that, I think because of our culture, because of the people we have, because I think we have a great team of people that we all thought we were really working together to build something. Our scientists feel ownership. I mean, they built this place.

**[0:15:18] George Yancopoulos:** They own this place. It's their company as well. Almost everybody withstood the ups and downs that we had. So almost all the key early people, and I'm not just talking about me and Len, I'm talking about the dozens and dozens of key scientists that really built this place, from the Neil Stahls to the Drew Murphys to the Jim Fandells to the Nick Papadopoulos, and so on and so on. All those guys are still here, and they're still excited, and we, in fact, feel like we're just getting started.

**[0:15:48] Luke Timmerman:** Now, this scientific culture that you're describing, I'm sure that resonates with a lot of people in biotech, especially at small companies. It's easier to maintain a culture like that when you're under, say, I don't know, 300 people maybe. And you probably were for a long, long time, the vast majority of your company's history. But now you're big. You've got five drugs on the market, maybe six. Six, yeah. 5 ,000. We keep careful track. I'm sure you do.

**[0:16:16] Luke Timmerman:** And you've got more than 5 ,000 employees now. Right. And suddenly, your job has to evolve. You have to pay attention to a lot more things. Can you describe that evolution?

**[0:16:30] George Yancopoulos:** Well, let me just point that, though. I mean, just because it is a point of pride, but it does reflect who we are. I think it's the first time in history that any company has gone from scratch, has gotten six drugs approved, and all six came from its own labs, all based on its own foundational technologies. I mean, it's really astounding. That's not how the rest of the drug industry works, where everything is, you know, somebody buys a company, somebody licenses something in, you know, drugs to go through.

**[0:17:00] George Yancopoulos:** It was discovered in academia, and then one small company buys another small company, buys another, you know, finally Pfizer buys it and that and then brings it, you know, forward. So it really is impressive. And I think it really reflects who we are and how we're different. But how do we stay different? I think that's a great question. I think that though we have more than 5 ,000 people, we're not really one monolithic company. I mean, we have different groups within us that have, you know, in some cases their own cultures.

**[0:17:29] George Yancopoulos:** Some of them have been built sort of as separate modules. I think we have the greatest manufacturing capability in the business, all internally built. I mean, from the people who are more on the research and science side, who develop the technologies and the cell lines and so forth, to the people in process development who then scale them up, to the people who are manufacturing at large scale, where we now have two plants, one up at Ronsolier and one in Ireland, in Raheem in Ireland.

**[0:18:01] George Yancopoulos:** Those people have a different culture, but it's very tied to our culture. They've sort of built, in many cases, their own parts, modules of this company. And they deserve enormous credit, tied very much to the rest of our culture and so forth. But by having essentially sub-companies and sub-efforts within it, while we can all stay part of the same unit, we do share so much in terms of our beliefs and our cultures. The research unit, for example, which has to be the most innovative and be protected in some way, still stays that way.

**[0:18:40] George Yancopoulos:** And it's still only a few hundred people that are really driving that, still led by the same, that brain trust that we built over the years of a few dozen really top scientific leaders that I think are some of the greatest scientific minds of our time. We all still work together. We all still get together regularly, literally several meetings a week, where we discuss the programs that are going on in research. And in many ways, why?

**[0:19:07] George Yancopoulos:** Because we love it so much. It hasn't changed. It's many of the same people incorporating young, new people, bringing in some new ideas and fresh perspectives, but melding with and synergizing with the experience and all the knowledge that we've built over the years. I think it's a great way to both maintain and further empower our research efforts. So the research effort is still relatively small, protected, run using the same principles that we built it in over the last 25 years.

**[0:19:44] Luke Timmerman:** Now, to play the devil's advocate, someone else in industry might be listening to this and say, well, this is great, George. You're riding high. You've been able to build it internally. Good for you. But most of science is widely dispersed. We have these external R &D strategies for a reason. There's great ideas. We don't want to suffer from hubris, as in the old not-invented-here syndrome. So how do you guard against that, kind of believing you're drinking your own Kool-Aid too much?

**[0:20:15] George Yancopoulos:** Well, no, I think that we do more collaborations with the outside world, both scientific and also corporate, than anyone else. But we do it from, I think, a different position, a real position of strength, where we're real partners and collaborators. I think the problem that a lot of pharma and even biotech companies get into is they think, well, we don't need the internal capability. We'll find it outside. When you do that, there's no counterpart to the great outside people.

**[0:20:47] George Yancopoulos:** And yeah, there's a lot of stuff going on that's great on the outside. But if you don't have the people on the inside who can really work with those people, push them, synergize and so forth. First of all, the company is not even respected. And all you're doing is you're giving money to people on the outside to do what they want to do. We do it in a different way where we have a position of strength on the inside.

**[0:21:06] George Yancopoulos:** We have the best scientists on the inside. And any field that's important, we feel like we're leaders in that field. But we don't necessarily feel like we can do it all alone. So whether it be that we establish a major collaboration with somebody, a top human geneticist like Wendy Chung at Columbia with our Regeneron Genetic Center, we're not giving her money. We're giving her capabilities and expertise, which she can't get anywhere else, which empowers her science.

**[0:21:32] George Yancopoulos:** And we're working from a position of strength where we're not just subsidizing, paying people to do work for us. We're using our signs to engage them and do even better, bigger signs. We do the same things with outside companies. When we collaborate with, you know, I can imagine if a big company says, oh, we've got to get into this new CRISPR, this gene therapy space. We're going to buy a company or we're going to invest in a company and so forth.

**[0:21:57] George Yancopoulos:** No, we believe we have some of the best capabilities. We've been doing genetic engineering. We've been playing with CRISPR as long, if not longer, than anybody else. But we recognize that an outside company like an Intellia actually has something to bring to the table. And they can do a lot of things that maybe we don't want to be investing or maybe we're not as good at doing as them. But we work with them in a position of strength because we take our capabilities and our technology and we try to help them.

**[0:22:24] George Yancopoulos:** We try to empower them. And it's really a collaboration of equals. So whether it's the examples with the great academic groups or it's examples with the new biotech capabilities that we're excited about, when we do these collaborations, we're doing them in a much, much different way. So we believe there's a whole outside world out there, but we can access it, we think, much more powerfully by having our own capabilities in-house to leverage what's going on out there.

**[0:22:53] Luke Timmerman:** So by keeping your internal team out there on the edge of science, you're not caught flat-footed, so to speak, in a position where one day you wake up and realize the pipeline isn't very promising. We're sitting on a mountain of cash. We've got to go out and buy some company for $10 billion.

**[0:23:13] George Yancopoulos:** Yeah, I think that's where people come into trouble. Because if you don't have the internal science and the capability, you can't even accurately judge what outside company to buy, what outside technology to trust. So when we're in it, we can evaluate, hey, if there's somebody out there that's really worthwhile, whether it's an Intellia or it's an Addisett or it's another company, we say, hey, yeah, we want to work with them. Whether it's outside academics, we say, hey, yeah, they're bringing something important to the table.

**[0:23:40] George Yancopoulos:** And we can judge that. We're not just, you know, doing intellectual, you know, adventures and saying, oh, who should we buy? And it's all done by consultants, which is unfortunately how it's done in the rest of it. It's done by top scientists on the inside saying, yeah, we can work with these guys. Together we can do better.

**[0:24:01] Luke Timmerman:** Now, you guys certainly do have a great track record, six FDA-approved drugs, a couple quite recently. And I think of the history, well, I want to get to this a little bit later, sort of the pre-ILEA and post-ILEA timeframe. But very, very few companies ever develop more than one. A successful company often gets two. Now you're in a really enviable position having done it multiple times. But still, the industry has this really fundamental problem with R &D productivity.

**[0:24:31] Luke Timmerman:** And I talk to lots of people, entrepreneurs, venture capitalists all the time, about various ways we're going to put a dent in this, whether it's genomics-based precision medicine or induced pluripotent stem cells or organs on a chip or you know now we hear a lot about artificial intelligence you know deep learning when we look at multiple layers of data between the genome the metabolome the proteome try to find patterns here that the human mind just can't see i mean do when you look at all this stuff i'm sure you look at all of it under the sun do you see anything there that you think is really going to make a difference and bring down the time, the risk,

**[0:25:10] Luke Timmerman:** the expense?

**[0:25:11] George Yancopoulos:** Well, that's the thing. Too many people count on one trick, okay? And they're one trick ponies, okay? I don't think it's ever going to be about one trick. It's sort of what we were just talking about. It's not the fact that we have the best human antibody technology in the world. That's not enough. it's not that we have the best human genetics capabilities in the world now we're the largest sequencing operation on the planet in terms of sequencing humans that's not enough it's not that we actually have the best biology deep research groups and it goes on and on it's that we have all of it.

**[0:25:57] George Yancopoulos:** And that's the thing that people don't appreciate. This is biology. Life is complicated. Understanding life and disease is really, really complicated. You have to be deep. You have to be broad. And it's impossible to count on one thing. Everybody's always looking for that next one thing. They're hoping like, you know, that great app that makes a difference. Unfortunately, high tech is a lot simpler than biotech. Okay, it's a lot easier to make it in that world.

**[0:26:31] George Yancopoulos:** In our world, it's about understanding life. And like I said, the numbers say, as you said, very few companies, you know, out of the thousands and thousands biotech, almost none come up with one drug. Okay, the ones that come up with more than one drug become glorified. Okay, the ones that come up with six, there's only one of those. Okay. And why is that? It's because we are so deep. We're so committed and we're so broad and there's not going to be one trick.

**[0:27:02] George Yancopoulos:** We believe in all of these things, everything that you bring up. We're heavily invested. We're trying. We're always working on the next thing. We're pushing every boundary that we can push. But if you're just in one space, if you're just trying one trick, it's all too complicated. Well, I don't have enough time all day to talk about all

**[0:27:21] Luke Timmerman:** of these things, but let's talk about one that you've made a conscious decision to invest in, and that's the Regeneron Genetics Center, the sequencing effort, largest in the world, you say. A lot of people would say, isn't this the domain of academia? Why? This is really early stage stuff.

**[0:27:34] George Yancopoulos:** Why do this in a company? Well, that's been our attitude the whole time, which is, yeah, there are things, obviously, that might be considered so early in the research landscape that it's probably not worth our investing in. But we fundamentally always believed that doing early stage fundamental research where you can see the applications, we have to be in it to win it. It doesn't mean we have to be in it alone. Like I said, we have collaborations with academic groups ranging.

**[0:28:09] George Yancopoulos:** I mentioned Wendy Chung at Columbia, the Hospital for Special Children, groups in every university all over the country as well as healthcare groups like Geisinger is important. We just recently announced a major initiative where we're going to be sequencing the UK biobank of 500 ,000 people. And we're looking for more such things. Yet these things in some ways are research, but they are so close to the heart of what biotech should be about. We're connecting and we've already realized that it works.

**[0:28:43] George Yancopoulos:** we're connecting human genetic variation to human disease and that's a great starting point. So already it's not that far from what we do every day. We've had drug programs that we were working on. We weren't quite sure if they were going to work or not. We found out that there's genetic variation in humans that supports the notion that yes, blocking that pathway is going to help in this disease. Okay, that gets us much more excited and more importantly, provides us a lot more motivation to really push that pathway, let alone the new discoveries that we make where we find the gene.

**[0:29:22] George Yancopoulos:** Oh, this gene variation protects against this azine or this gene variation causes that. This is where all the great stories start. Well, this is like the PCSK9 story. Exactly. Well, Our first drug approval, which is our IL-1 trap or ARKELIST in cold-induced inflammatory syndrome, was perhaps the first example, one of the really first examples other than the deficiency diseases, of going from a human genetic disease, mapping it, understanding it, seeing what the pathway was, coming up with a human biologic that blocks it, and having overwhelming benefit.

**[0:30:03] George Yancopoulos:** 85 % average improvement in a horrific disease. That's how you want genes to work. That was one of the first examples. And now, as you said, PCSK9, where we got the first approved anti-PCSK9 agent for lowering cholesterol and hopefully soon to have even stronger data suggesting that it be preventive in heart disease. That's now one of the most heralded examples of going from a gene discovery by our collaborators, Helen Hobbs and Jonathan Cohen down in the University of Texas Southwestern.

**[0:30:32] George Yancopoulos:** It's another example of another great group that we work with and we synergize with because we bring things to the table for them that has led to a great story. And in fact, almost all of our stories, all of our new medicines have a major human genetic component that drove them.

**[0:30:51] Luke Timmerman:** Now, you're talking a lot about the successes of Regeneron and you have every right to. But part of the job of the chief scientific officer is to kill programs that aren't working. You're always working on imperfect or incomplete data sets when you have to make these decisions about how to spend the company's resources. Can you point to an example of maybe a project that you've killed or how you came to that decision?

**[0:31:15] George Yancopoulos:** Yeah, well, I don't know if it's really killing them. It's more that the projects where the data becomes stronger and stronger is always accumulation of more and more information and data. Like I said, we might have a little human genetics data, which we then pursue. And if the human genetics data looks stronger, then we continue to pursue it. And then maybe we do a humanized genetic model in a mouse. And if that looks good, then we pursue it.

**[0:31:43] George Yancopoulos:** And then we make, let's say, a fully human antibody, and we try it in the genetically humanized mouse model. And then it works. And as the data accumulates, the story gets stronger and stronger. And then, like I said, you just keep pushing it and keep pushing it and keep pushing it. So it's more a matter of where you invest your resources as the stories get stronger. We've had very rare cases of when the data starts accumulating more and more and more and we start pushing it, that we get late stage failures.

**[0:32:15] George Yancopoulos:** That is seen all over the rest of the industry.

**[0:32:18] Luke Timmerman:** Happens all the time.

**[0:32:19] George Yancopoulos:** Does not really happen with us. Why? Because it's such an accumulation of knowledge and data that keeps driving us forward that by the time we're pushing things, okay, at that point, you know, we rarely see failures. As, you know, Roy Vagilis has told us, by the time we get into late stage data, we should be very, very sure about what results are going to show.

**[0:32:43] Luke Timmerman:** So if you're in an early stage program and say that early signal that you thought you saw starts to fade, what do you do then? Do you just kind of dial back the funding?

**[0:32:52] George Yancopoulos:** That's basically what we do. Exactly. We basically pause things at whatever stage and we try to get better and better data. So I think a lot of other people push forward in the absence of data. We just don't push forward in the absence of really strong data in many cases. There is a couple examples that I could point to where we have done it for competitive reasons, where we didn't think the data was strong and other people were moving forward.

**[0:33:19] George Yancopoulos:** And we have the capability. We had the capability of pushing things in the clinic. And we said, OK, we're going to try it even though we don't think this is going to work. But most of the time when we push things forward, it's because we have, we think, overwhelming data packages, which is why we've been so rarely wrong in late stage trials.

**[0:33:35] Luke Timmerman:** You mentioned competition. I'm glad you did because that's part and parcel with success. A lot of people start looking at you. They start to mimic you. You can probably hear the competitive footsteps every day. I mean, Amgen's out there with their PCSK9. Just the other day, AbbVie released some JAK1 inhibitor data that may be competitive with Dupixin. How do you think about the competition?

**[0:34:02] George Yancopoulos:** Well, it is interesting because we are so broad in that we're working across so many areas that it really is us against the world. And though I think invariably any one competitor would be hard for them to sort of keep up with us, of course. When there's 5 ,000 companies out there, yeah, one of them will compete with us in PCSK9 and we'll do well. I mean, you bring up Amgen. I think that, you know, they've done a great job developing their antibody in PCSK9.

**[0:34:31] George Yancopoulos:** It's clearly a very effective agent. On the other hand, many other companies have failed trying, including Pfizer, in a late stage, phase three trials stage after they spent billions, they failed, which shows how hard this business is. But when you're winning and there's 5 ,000 competitors, there's usually going to be one or two that are going to also be there challenging you. Like, Depixen is a great story where we're quite ahead of the competition. It's a first-in-class, spectacular new treatment that really seems to be attacking the core, the fundamental drivers of maybe all allergic disease.

**[0:35:15] George Yancopoulos:** And that's why it's getting so many people excited. And the data's already approved in atopic dermatitis where it got breakthrough status. And the data is really stunning in terms of how it can really make a difference in patients' lives. But like you said, when people see that, everybody's going for it. Everybody's gunning for it. They want to follow on and see if they can get a little piece of that pie.

**[0:35:38] Luke Timmerman:** Now, I saw you give a talk recently where you mentioned that Regeneron has never raised prices of its drugs. This is the biggest issue in the industry, the big rub in between how it interfaces with society. Now, I think in order to understand this, I think you have to come back to the ILEA case And I looked at this before coming in today I mean, it looks like to me that an economist would look at that story and say Well, you came into the VEGF space with a drug for wet acute age-related macular degeneration And a pretty similar clinical profile to Lucentis that was out there from Genentech but there was a giant gap in the market.

**[0:36:25] Luke Timmerman:** There was a high-priced Lucentis and then there were compounding pharmacies that were taking small doses of Avastin that were real cheap and they could get comparable data. You came in and undercut Lucentis on price, having done the proper clinical trials to give the FDA and reimbursers the confidence in your data set. But you did this rare thing in the industry where you actually, as I say, an economist would say, competed on price. Similar product, lower price.

**[0:36:53] Luke Timmerman:** And it has turned out to be a real winning strategy. Can you talk about that thought process? I think that it wasn't that we really undercut the

**[0:37:01] George Yancopoulos:** Lucentis price because basically per injection, we were just a few dollars lower. We did that deliberately because we thought that we didn't, even though we thought we had a premium product. I mean, that was the big driver, I think, the difference. I mean, basically it turns out that we actually had the clinical trial data that showed that, you know, these drugs have to be injected into the eye. We actually showed head to head that we can inject half as frequently and get as good data.

**[0:37:30] George Yancopoulos:** That's a big, big advantage. Not only that, even with the less injections, we actually showed the fundamental problem that you get in the eye, you get swelling in the back of the eye. We did a better job of controlling that swelling, even with the less injections. And then we still, on a per-shot basis, provided a little bit of a lower price compared to Lucentis. I think what really drove the fact that ILEA has been a blockbuster, and it's really a really rare case where it's still growing after five and six years, one never sees that.

**[0:38:09] George Yancopoulos:** And why is that? Well, it's because the drug really works. It really makes a difference in terms of drying out the eye and in terms of blocking VEGF. And now, as you probably know, the National Eye Institute and the National Institutes of Health did side-by-side studies, which are rarely done, comparing us to both those other approaches that you mentioned. And in their studies, we beat them by one to two lines on one of these eye charts, which is huge.

**[0:38:43] Luke Timmerman:** George, hearing everything that you're saying here, most companies would look at this same kind of data set and say, well, we've got a premium product. We'll price it at 20, 30, 40% more. And that's how we've gotten into this kind of arms race of pricing.

**[0:38:57] George Yancopoulos:** Well, yeah, I think that maybe other companies would have done that. I think that, like we always say, I mean, we believe we're sort of the legacy of Roy Vagilis and what he brought to the industry and what he meant to the industry in terms of fair and appropriate pricing. We think that we did a good job of doing a fair and appropriate pricing there. I think that we've also been acknowledged. Our most recent launch with Dupixent, where we priced in a brand new space.

**[0:39:29] George Yancopoulos:** There was no other biologics for atopidermatitis. Atopidermatitis is considered as serious, if not more serious, a disease than psoriasis. There's multiple competing drugs for psoriasis. we price our drug at less than half the price of the average psoriasis drugs just because we think it's the appropriate thing to do. We do think that appropriate drug pricing and fair drug pricing and what's going on in the industry, you know, might in some ways be hurting the industry in terms of people trying to get every last penny out of their prices.

**[0:40:00] George Yancopoulos:** We think in the long run it's better to be responsible and to be fair about drug prices. But I do think that what we should also recognize is though this is an important short-term problem that we should all talk about. And I think that we're representing good leadership here in terms of in these cases where we've been acknowledged by the outside world that we're not one of the bad players. We're doing things responsibly. But because we're innovating and we're bringing you important drugs and drugs that, based on their capabilities, are really continuing to grow, that's why we can afford to do fair pricing.

**[0:40:37] George Yancopoulos:** But that really gets at the crux of the issue that people don't understand. If today we just, as an industry, just gave all of the drugs away for free, okay, what would that do in the long run? Okay, that would kill the greatest innovative healthcare capability in history, which is that of the United States, which is not doing well enough as it is, but it's still the greatest that exists in the world. What we should recognize is, yes, drug pricing and trying to be fair and responsible drug pricing is an important current issue.

**[0:41:11] George Yancopoulos:** We have to deal with it. But the much, much, much bigger issue is what you talked about before, is that people don't understand how to optimize innovation and productivity in R &D to bring important new drugs. If we don't come up with important new drugs for neurodegenerative diseases like Alzheimer's, for metabolic diseases like type 2 diabetes and obesity, for new infectious diseases that challenge us all the time, if we don't up our game as an industry, these drug pricing issues that we have now are going to just be a rounding error.

**[0:41:44] George Yancopoulos:** We're going to get drowned in disease, and we're going to have to do a much better job. That's the fundamental problem. And that's where I think we have to shift the conversation. The conversation has to be how, as an industry, maybe we can use Regeneron as a model, how more players in the industry can be more innovative, bringing more medicines to the world, doing a better job so that we can keep up with the impending healthcare epidemics that are otherwise going to doom us as a society.

**[0:42:14] George Yancopoulos:** And these current drug price issues are going to be trivial in comparison to what we're going to be dealing with when tens and tens of millions of people are going to be suffering from Alzheimer's or maybe a quarter of the country is going to have type 2 diabetes? What are we going to do there if we don't have drug? We need more investment in this space. We need more investment in the NIH, in the budget for the NIH.

**[0:42:36] George Yancopoulos:** It's a little silly from my perspective that we're investing as a nation $30 billion to attack what are arguably some of the most important challenges we have as a species. All of these impending medical crises, which is going to be spending, I would argue at least an order of magnitude more just in the basic research. But we should also come up with better incentive plans and better approaches to get the industry to do more R &D, more effective R &D, and figure out how to get better innovation out of the rest of the industry.

**[0:43:06] Luke Timmerman:** That's the central problem of the industry. And it really is on you guys. Nobody on the outside is going to fix that for you.

**[0:43:12] George Yancopoulos:** Yeah, well, I do think that if I was in government, that's what I'd be trying to figure out. because we have an old expression, okay? And basically it just reflects biology and evolution. You get what you select for, okay? So you're going to get the types of behaviors that you select for. If we could think a little bit better, not about trying to say, oh, bad guys, let's cut prices. Let's figure out how to lower costs.

**[0:43:40] George Yancopoulos:** Let's do this. No, what we should be thinking about, how do we create the right selective pressures in order to improve R &D investment and R &D innovation.

**[0:43:51] Luke Timmerman:** Now, you and Len have both been pretty outspoken about some of the bad behavior that you've seen and has been widely reported on in the industry. Guys like March Crowley, Valiant, etc. But even some members of the industry that continue to operate on that price increase every year model. That's sort of a way of papering over a lack of innovation. If you don't have new drugs coming out of the pipeline, you've got to increase your revenue somehow.

**[0:44:16] Luke Timmerman:** You raise it past the rate of inflation every year. I mean, you guys could raise the prices of your drugs in line with inflation, and nobody would bat an eye. Do you do that? Why wouldn't you do that?

**[0:44:31] George Yancopoulos:** Well, I think that we're, like I said, we're just trying to live up to the legacy and to the lessons from Roy Vagilis. And I think that we just believe that we want to do the fairest things possible while doing the best things for our business. And as you said, if you're innovating, if you're coming up with new opportunities, you can do that. But I think, as you said before, this is the major problem in the industry.

**[0:44:56] George Yancopoulos:** The problem is not that people like big companies and so forth are raising their drug prices. Yeah, that's a short-term problem. But that's really a symptom. It's not the actual problem itself. It's like the cough when you have lung cancer. The fundamental problem is the lack of innovation. So if Pfizer was coming up with dozens of new drugs every year, they wouldn't have to worry about depending on drug price increases to support their growth. It's because they can't do the drug growth that's causing the increase in the prices.

**[0:45:31] George Yancopoulos:** And that's what we have to address.

**[0:45:32] Luke Timmerman:** And you see other manifestations of this as well in the market, different flavors of it, let's say. Like last week, Allergan comes out with this patent gambit where they transferred over to an Indian tribe with sovereign immunity so that generic companies can't challenge their patents in court. I mean, to protect a franchise for dry eye. I mean, what is that all about? What's your reaction to things like that?

**[0:45:54] George Yancopoulos:** Well, I do think, you know, and Len's done a great job, I think, highlighting this point. I think the patent system, which is encoded in our Constitution, and it's intended to drive innovation, and it's actually a deal that the government does with innovators. That in the short term, if you innovate, you're entitled to, for a short period of time, a great return on that innovation. You deserve it. And that should be the driver of innovation. But at some point, the return back to society is that the patent runs out and people are able to now produce the product and provide it at much lower cost because the patent runs out.

**[0:46:39] George Yancopoulos:** So I think that system sort of works. That's part of what I was talking about. We have to protect innovation. We have to create the incentives for innovation. But it has to be done in a fair way. And I think our Constitution tried to do that and did a great job of it. And we just have to continue to try to protect the right way of promoting innovation, but eventually also allowing the benefits to society at a much lower cost.

**[0:47:04] George Yancopoulos:** So, yes, patents should run out.

**[0:47:07] Luke Timmerman:** They shouldn't go forever.

**[0:47:08] George Yancopoulos:** They should not go forever.

**[0:47:10] Luke Timmerman:** A couple of personal questions. You and Len have been working side by side for however many years. I mean, this is a rare thing. I don't think you ever, I mean, I don't know anybody who's worked with anybody side by side for close to 30 years. How long do you want to keep doing this?

**[0:47:28] George Yancopoulos:** Well, we have a few good models, by the way. There are other people. You know, we always point to our own famous board of directors, Brown and Goldstein, Nobel Prize winners that have been working together since the 70s. They're still inseparable. We just, you know, we had our board directors meetings last week. We just spent a lot of time with them. And in some ways, you know, as Len said, it's sort of like either a married couple or I like to think instead of it as like brothers.

**[0:47:56] George Yancopoulos:** OK, if you see us and, you know, other people see us all the time, you know, we bicker, we fight, but we have such enormous respect and true, you know, underlying love for each other. I appreciate Len. I think that he's one of the smartest guys in the world. But even more importantly, he's one of the most ethical guys in the world. And I think that he is driven by the right motivation. I mean, number one, you know, he was raised on the same mantra I was.

**[0:48:20] George Yancopoulos:** His dad gave him the saying about doing well by doing good. And he he lives by that. He breathes that. OK, I believe in the same things. And when we argue about things, we're arguing about theories and we're arguing about approaches and we're arguing about, oh, is this the best thing to do or that the best thing to do? But fundamentally, we're all after the same thing. We're all interested in the same thing. And, you know, Len gives a great story about how he knows, you know, we'll have been doing this too long.

**[0:48:47] George Yancopoulos:** The things that we most argue about, unbelievably enough, after 25 or almost 30 years now, are basic scientific theories underlying disease and what we should be doing in terms of pathways we should be exploring. That's what we argue about. And he always says, you know, if we're in one of our offices arguing with each other about that and somebody comes in, you know, waving this week's sales numbers, if we stop our argument so that we can check out the sales numbers, we know that we're done for.

**[0:49:19] George Yancopoulos:** But we have a great relationship and it extends beyond, I think, me and Len. I think that, you know, maybe we sort of set the example. But it's the same way. When you're talking about, you know, how we interact with other key senior leaders here, a Neil Stoll or a Drew Murphy, or now we have a new head of clinicals doing a great job, David Weinrich, and the names go on and on. We have these great relationships where we're not afraid.

**[0:49:45] George Yancopoulos:** We're not afraid to mix it up. We're not afraid to argue, but we're arguing, you know, about the facts.

**[0:49:51] Luke Timmerman:** Well, you got your eye on the mission. You're not taking your eye off the ball. Like the famous, you know, Apple story between Jobs and Scully. You're probably familiar with this, right, where Jobs was obsessed with creating the best possible product. And then this new CEO comes along and he's obsessed with hitting the quarterly numbers. Big difference. And the whole organization takes on that different kind of ethic. Yeah, and the same thing could happen. You take your eye off the ball.

**[0:50:19] George Yancopoulos:** Well, as I was saying, I mean, you know, the great thing is I think we're all in it together. and like Len always says, you know, he learns the quarterly numbers every quarter and a few weeks later he forgets them all because that's not what's important. Well, you need the money

**[0:50:35] Luke Timmerman:** to make, to keep the enterprise going. It's not to trivialize that. This isn't, you know, charity. Right. This is a business, but it can't be the absolute defining obsession. Well, but the other

**[0:50:46] George Yancopoulos:** thing about it is when, you know, this is a long-term business and this is what a lot of people don't realize. And if you worry about the short-term fluctuations, you get distracted in the wrong way. We shouldn't be worrying about this week's quarterly numbers. You know what we're worrying about? We're worrying about the quarterly numbers five years from now and 10 years from now. And that's why we're all so different, okay? Most people, most leaderships, you know, like I said, gone are the days of the Roy Vagiluses, okay?

**[0:51:17] George Yancopoulos:** In almost every company, leadership is there for three, four, five years. They're not worried about R &D. You know why they're not worried about R &D? Because they're not going to survive to see the fruits of that R &D. So to them, the R &D is just an anchor that's dragging down their quarterly profits. For us, we still plan. I still plan on being here forever, God willing. Okay. And like I said, many of us feel like we're just getting started.

**[0:51:43] George Yancopoulos:** So we're still thinking five, 10, 20 years down the road because those are the time frames you have to be thinking about. And if you get distracted by meaningless quarterly fluctuations or the daily stock price or things like that, you're not really looking at long-term growth. This is a long-term game. This is an endurance race. And this is a situation where the winners are the ones who are defined, not by what happens this month and next month and a year from now, but years from now.

**[0:52:11] George Yancopoulos:** We plan to still be here and still be innovating. And that's the thing that I have to say, one of the things that I'm proudest about, I just learned that for I don't know how many years in a row, we just got voted among the top 10 most innovative companies in the world across all industries. So when we started this, that was the knock against us. That was the rub. Oh, these guys are so innovative and all that.

**[0:52:31] George Yancopoulos:** They don't know how to come up with drugs. It's a science project. Yeah, exactly. They were saying, you know, it's a science project. They don't know how to come up with drugs. Well, guess what? We know how to come up with drugs. But the thing that I'm proudest about is we're still recognized 25, 30 years into our life cycle as still being among the most innovative companies in the world. I think we're still the innovation leader in our space.

**[0:52:51] George Yancopoulos:** And that's what I'm proudest about because I think that's never going to end because that's in our genes. It's who we are.

**[0:52:58] Luke Timmerman:** Well, and this is reflected in the taking on the sponsorship of the science talent search, the Regeneron Science Talent Search. I mean, the Junior Nobels, some people call it, right? Right. I mean, that's really an example of that long-term thinking.

**[0:53:10] George Yancopoulos:** Yeah. An example of our long-term thinking is, I think that this summer we had 250 interns. Okay. We do the intern project because we feel like we should be giving back. But believe it or not, we've been around long enough that we have people who start out as interns here who are vice presidents now leading major efforts. In fact, the head of our Regeneron Genetic Center started as an intern here. And that just shows that we believe in the next generation.

**[0:53:36] George Yancopoulos:** we believe we can help them. And what we want them to do is to stand on our shoulders to take it to the next level. And that's what I think this is all about. This is all about, you know, this is all about all of us as a species working together, helping each other going forward. And we're one example, I think, of a company that's figured out how to do it right. And we're about it for the long term.

**[0:53:58] George Yancopoulos:** And that's why we sponsor the Regeneron Science Talent Search, because we want to inspire the next generation. So many of us, including Len and I, are actual alumni of that program. And for us, it changed our lives. Well, we want to change the lives of the next generation. We want to take interns now, and we want those interns to get inspired. We want them to see how it's done. And if some of them come back and do it here and help take us to the next level, that's the dream.

**[0:54:24] Luke Timmerman:** I actually rode in my shuttle bus from the hotel here today with an intern at Regeneron. And she didn't know I was a reporter. and she said some quite nice things. So I thought you'd probably like to hear that.

**[0:54:37] George Yancopoulos:** She probably, I hope, told you that we meet. I meet with the interns on a regular basis because I want them to know how important they are and that they are the future and that we're counting on them.

**[0:54:47] Luke Timmerman:** Last question. What's a good book that you've read recently? Hood, Trailblazer of the Genomics Age. Well, that's very much appreciated, but other than mine.

**[0:55:01] George Yancopoulos:** It's interesting. I am not, I have to say, an avid reader. I guess maybe I don't have enough time for it, though I do have four kids. And this summer, one of my kids made me read a book, which I actually thought was really interesting. And maybe did actually, even though it was written almost 100 years ago, did actually point to some issues in our society today. It was a book called Fountainhead by Ayn Rand.

**[0:55:30] Luke Timmerman:** I'm familiar.

**[0:55:33] George Yancopoulos:** Yeah, I think it pointed to the fact that we do, I think, in our society, have to figure out ways to highlight the people who can really move society, the people who can really innovate. and that we want to use them as great examples for the next generation and that maybe that's what young people have to see, that the people who can really make a difference, who can really push humankind forward, I mean, that's what people want to be striving to do.

**[0:56:08] Luke Timmerman:** Well, if you guys are able to solve the fundamental R &D problem that the industry is up against, it will relieve some of the pressure on some of these other issues we've talked about.

**[0:56:20] George Yancopoulos:** You know, we are doing our share. It's a matter of, and I think other people are hopefully beginning to see it, it's a matter of can we get other people to follow our example? Can we get other people to realize it's a long game? Can we get other people to realize that it takes a lot of investment of years to build something of fundamental value and strength that is really broad and deep that can really then take on the problem?

**[0:56:43] George Yancopoulos:** You know, we have to fight against all the incentives right now to try to turn it into a short game. That's what I was talking about. You know, if I was in government and policy right now, I'd be trying to change the games. I'd be trying to change the incentives. So I'd be trying to select for long behavior, for the people who are really going to make a difference over the long term, because that's what really matters.

**[0:57:07] Luke Timmerman:** Well, that's all very in line with the theme of this show. So, George Yancopoulos, thanks for joining me today on The Long Run.

**[0:57:15] George Yancopoulos:** Luke, I really appreciate it. It was a lot of fun.

**[0:57:20] Luke Timmerman:** Thanks for listening to The Long Run, a production of Timmerman Report. Music for this show comes from D.A. Wallach. Pedro Rosado of Headstepper Media was the producer and editor. Todd Bennings created the logo. Next on The Long Run, I speak with Richard Popps, the CEO of Alchemist. In this episode, we talk about the opioid painkiller addiction crisis and what his company can do about it. Alkermes has one of the very few anti-addiction drugs available on the market.

**[0:57:51] Luke Timmerman:** But it's not a simple, straightforward story. The drug is not for everyone, and this issue is hard to talk about at times. Don't miss this upcoming episode of The Long Run.
